JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Inclusion Criteria

• Written informed consent.
• Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
• ECOG performance status score of 0 or 1.
• Has been treated with at least one line of systemic therapy for that tumor type and stage.
• Have documentation of confirmed TP53 Y220C mutation.
• At least 1 measurable lesion per RECIST v1.1.
• Adequate hematological, renal and hepatic function and appropriate coagulation condition.
• Able to swallow and retain orally administered medication.

Exclusion Criteria

• Active brain or spinal metastases or primary CNS tumor.
• Active infection requiring systemic treatment within 7 days.
• Active HBV or HCV.
• Any severe and/or uncontrolled medical conditions.
• LVEF ≤50% assessed by ECHO or MUGA.
• QTcF>470 msec.